Maria Thacker, President & CEO of Georgia Bio, Elected as New Board Chair for the Council of State Bioscience Associations (CSBA)

The Council of State Bioscience Associations (CSBA) today announced the election of new board members to its Board of Directors for the next two-year term (2022-2023). CSBA also announced new board leadership, including new Chair of the Board of Directors, Maria Thacker, President & CEO of Georgia Bio.


“We are thrilled to announce our new slate of incredibly accomplished and esteemed board leaders for the next exciting phase of CSBA,” said Michele Oshman, Executive Director of Council of State Bioscience Associations (CSBA) and Vice President of External Affairs at the Biotechnology Innovation Organization (BIO). “From the global threats of pandemics and climate change to the growing impact of bioscience on local jobs and economies, our industry faces many important challenges today. We look forward to continuing to work together across our new board leadership, members, and stakeholders to confront these threats and expand opportunities for innovation.”


CSBA is pleased to announce the following leaders and members of the board of directors for the 2022-2023 term:


• Maria Thacker, Board Chair
President & CEO, Georgia Bio
• Kelvyn Cullimore, Board Member
President & CEO, BioUtah
• Michael Fleming, Board Member
President, Delaware Bio
• Laura Gunter, Board Member
President, NCBIO
• Sonia Hall, Board Member
President & CEO, BioKansas
• Debbie Hart, Past Chair
President & CEO, BioNJ
• Liisa Bozinovic, CSBI Representative
Executive Director, Oregon Bio

The new leaders and members of the board of directors will join existing members serving for the 2021-2022 term:


• John Conrad, Board Member
President & CEO, iBIO
• Mike Guerra, Board Member
President & CEO, California Life Sciences
• Dawn Hocevar, Board Member
President & CEO, BioCT


“I am honored to be the new CSBA Board Chair and pledge to continue elevating the critical work of state biotechnology associations nationwide,” said Maria Thacker, Board Chair, CSBA and President & CEO, Georgia Bio. ”Our associations play a central role in championing the groundbreaking work of the biotechnology sector as we innovate for human health discoveries, agricultural advancements, and environmental sustainability.”

“It has been my honor to serve as the CSBA Board Chair over these last two years,” said Debbie Hart, Past Chair, CSBA and President & CEO, BioNJ. “Our state associations have faced immense challenges on the policy arena as well as an unprecedented global pandemic. I am proud of what we have collectively accomplished in helping to stave off grave policy proposals, offering unique educational opportunities, and supporting our Members, all despite operating remotely in a time of immense change for our country. I am delighted to see the very talented Maria Thacker take over as the new CSBA Chair and look forward to supporting her in that role and to our ongoing collaboration on behalf of our industry.”

About The Council of State Bioscience Associations


The Council of State Bioscience Associations (CSBA) is a confederation of state-based, nonprofit trade organizations each governed by its own board of directors convened by the Biotechnology Innovation Organization (BIO). The common mission of the members of the CSBA is to promote public understanding and to advocate for public policies that support patient access to lifesaving therapies and the responsible development of the bioscience industry.

January 20, 2026
January 20, 2026. Paulding County has been designated a BioReady Silver Community by Georgia Life Sciences, the state’s leading life sciences membership organization. The BioReady designation recognizes communities that demonstrate strong zoning practices, infrastructure capacity, and readiness to support biotechnology and life sciences development. “We are proud to recognize Paulding County as our newest BioReady Silver community,” said Maria Thacker-Goethe, President and CEO of Georgia Life Sciences. “Paulding County’s proactive planning, growing workforce, and access to regional healthcare and transportation infrastructure position it well to support life sciences manufacturing and commercialization. Through the BioReady program, we champion communities that are intentionally preparing to compete for industry investment and job growth.” Paulding County’s designation reflects its commitment to thoughtful land-use planning, scalable infrastructure, and business-friendly development policies that support life sciences and advanced manufacturing uses. Located in the northwest Atlanta metro region, the county offers access to a strong labor pool, major transportation corridors, and regional healthcare systems, making it an attractive option for biotechnology, medical device, diagnostics, and related life sciences companies seeking room to grow. “Georgia BioReady designation validates Paulding County’s readiness to support bioscience investment and strengthens our position as a growing hub for advanced industries,” said Alex Almodovar, President & CEO, Paulding County Economic Development Inc. & Industrial Building Authority The BioReady rating system evaluates communities across three tiers—Bronze, Silver, and Gold—based on their readiness to attract and support life sciences facilities. Through these ratings, Georgia Life Sciences helps municipalities better showcase biotech-appropriate sites, strengthen infrastructure planning, and clearly identify life sciences-friendly locations. This approach enables communities like Paulding County to compete more effectively for private investment and high-quality job creation. Georgia Life Sciences advances innovation, strengthens the workforce pipeline, and grows Georgia’s life sciences economy through the BioReady Community program, modeled after MassBio’s nationally recognized rating system, which assesses a community’s readiness to host life sciences facilities based on zoning practices and infrastructure capacity. About Georgia Life Sciences Georgia Life Sciences, founded in 1989, is a non-profit, membership-based organization that promotes the interests and growth of the life sciences industry. It is the state’s largest and most influential life sciences advocacy and business leadership organization working to improve access to innovative discoveries that have lifesaving impact. The association connects business, academia, government, and other allied entities involved in the application of life sciences products to fuel growth and collaboration through policy development, community programs, national industry initiatives, and a portfolio of educational and networking events. Learn more at galifesciences.org.
January 14, 2026
What happens when students see real work before choosing a future 
January 8, 2026
By: Patrick Plues | RealClearHealth January 8, 2026 For decades, America has led the global biotech industry – thanks, in part, to state-level policies that encourage research and manufacturing investments. But other countries, including China, are sparing no expense in the bid to overtake us. Beijing has officially made biotechnology a national strategic priority and is pouring billions into state-backed research and manufacturing efforts. All states should consider impactful biotech policies that grow and strengthen our domestic biotechnology industry. If states fail to utilize and replicate what are considered to be the best and most successful policies in biotech-focused economic development, the United States will soon lose its long-term leadership in developing medicines and medical technologies, which underpin our health, our economy, and our national security. Thankfully, many governors and state legislatures around the country are already answering this call -- as our new study, The U.S. Bioscience Industry: A Powerful Engine for State Economies, demonstrates. Keep Reading at https://www.realclearhealth.com/2026/01/08/americas_biotech_leadership_depends_on_the_states_1157584.html
MORE POSTS